Physician profile
Ramez N Eskander
NPI 1144486929
$706,485.32
in general payments reported to CMS, 2019-2025
38 companies · $170K in 2025
The $170K reported for 2025 was more than what 99% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $66K · 2021: $63K · 2022: $78K · 2023: $115K · 2024: $112K · 2025: $170K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $214K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $107K · Travel and Lodging: $64K · Food and Beverage: $6,645 · Honoraria: $2,400 · Education: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $213,922.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,490.76 |
| Travel and Lodging | $64,411.76 |
| Food and Beverage | $6,644.60 |
| Honoraria | $2,400.00 |
| Education | $2,139.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $202,352.99 | 2019-2025 | Keytruda |
| Astrazeneca Pharmaceuticals Lp | $153,623.75 | 2019-2025 | Lynparza |
| Eisai INC. | $73,270.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $56,469.74 | 2020-2025 | Jemperli, Zejula |
| Astrazeneca Uk Limited | $28,550.95 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Clovis Oncology, INC. | $23,564.84 | 2019-2022 | |
| Abbvie INC. | $22,383.57 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $22,045.44 | 2023-2025 | |
| Genmab U.S., INC. | $19,113.19 | 2022-2025 | Epkinly, Tivdak |
| Seagen INC. | $18,902.99 | 2021-2023 | Tivdak |
| Daiichi Sankyo INC. | $15,869.16 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $15,331.79 | 2020-2022 | |
| Immunogen, INC. | $6,852.05 | 2023-2024 | Elahere, Elahere |
| Corcept Therapeutics | $5,483.81 | 2024-2025 | Korlym |
| Biontech Se | $5,436.71 | 2023-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $5,200.00 | 2025 | |
| Gilead Sciences, INC. | $5,170.36 | 2023-2025 | |
| Beigene USA, INC. | $3,900.00 | 2024 | |
| Eli Lilly and Company | $3,482.00 | 2025 | |
| Eisai Co., Ltd. | $3,160.00 | 2023 | |
| Incyte Corporation | $3,148.00 | 2024-2025 | |
| Aadi Bioscience, INC. | $3,106.00 | 2023 | Fyarro |
| Novocure Gmbh | $2,400.00 | 2023 | |
| Tesaro, INC. | $2,154.30 | 2019 | |
| Pfizer INC. | $2,005.63 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $1,722.00 | 2021 | |
| F. Hoffmann-La Roche Ag | $760.00 | 2024 | Tecentriq |
| Intuitive Surgical, INC. | $336.54 | 2019-2020 | |
| Foundation Medicine, INC. | $229.00 | 2022 | |
| Novocure INC. | $166.03 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $136.45 | 2023-2025 | Xpovio |
| Genentech USA, INC. | $126.78 | 2019 | |
| Amgen INC. | $17.32 | 2020 | |
| Medical Device Business Services, INC. | $13.14 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramez Eskander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.